Thiago Favano: Can BOT/BAL Change the Treatment Landscape for MSS Colorectal Cancer?
Thiago Favano/LinkedIn

Thiago Favano: Can BOT/BAL Change the Treatment Landscape for MSS Colorectal Cancer?

Thiago Favano, Senior Director Clinical and Access Programs, Medical Education at Agenus, shared on LinkedIn:

“It was a privilege to join the Precision Oncology meeting hosted by Dr Tim Crook, Andy Gaya and the Cromwell Hospital team in London last week, as an invited guest.

More than 50 oncologists and healthcare professionals came together for an evening of open, practical discussion about where precision oncology and immunotherapy are heading, and how we can bring new options to patients who have run out of standard ones.

A highlight for me was Dr Andy Gaya’s presentation of a patient with metastatic MSS colorectal cancer successfully treated with botensilimab and balstilimab (BOT/BAL) under the named patient access program in the UK.

Real-world cases like this, shared openly between colleagues, are how the field learns fastest.

Thank you, Dr Crook, Dr Gaya, and the Cromwell team, for the invitation and for building such an engaged community. I’m looking forward to continuing these conversations in the new year.”

Thiago Favano: Can BOT/BAL Change the Treatment Landscape for MSS Colorectal Cancer?

You may also be interested in: UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer

Thiago Favano: Can BOT/BAL Change the Treatment Landscape for MSS Colorectal Cancer?